Clinical Scorecard: The High Cost of Medication: How a Copay Card Assisted Until It No Longer Did
At a Glance
Category
Detail
Condition
Psoriatic arthritis
Key Mechanisms
Autoimmune disease causing skin lesions and joint pain; managed with immunomodulatory medication Otezla
Target Population
Patients diagnosed with psoriatic arthritis requiring advanced therapy
Care Setting
Outpatient rheumatology and primary care
Key Highlights
Otezla is an expensive brand-name medication with a list price around $5,000 per 30-day supply.
Copay assistance programs can temporarily shield patients from high out-of-pocket costs but may be exhausted quickly.
Insurance plans may not count copay assistance toward deductibles or out-of-pocket maximums, leading to unexpected patient expenses.
Guideline-Based Recommendations
Diagnosis
Refer patients with skin and joint symptoms to rheumatology for evaluation and diagnosis of psoriatic arthritis.
Management
Consider Otezla for controlling symptoms of psoriatic arthritis when indicated.
Enroll eligible patients in manufacturer copay assistance programs to reduce initial financial burden.
Monitoring & Follow-up
Monitor patient adherence and symptom control, especially if medication dosing is altered due to cost concerns.
Risks
Risk of symptom relapse if medication is rationed or discontinued due to cost.
Potential financial toxicity from high out-of-pocket costs once copay assistance is depleted.
Patient & Prescribing Data
Patients with psoriatic arthritis prescribed Otezla
Copay cards may cover a limited amount annually (e.g., $9,450) but can be exhausted within months, leading to significant out-of-pocket expenses despite insurance coverage.
Clinical Best Practices
Educate patients about the potential limitations and expiration of copay assistance programs.
Coordinate with insurance and pharmacy benefit managers to clarify negotiated drug prices and patient responsibilities.
Encourage patients to plan financially for medication costs beyond copay assistance coverage.
Avoid medication rationing to prevent symptom recurrence and disease progression.
Consider alternative therapies or generic options where available and clinically appropriate.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
